Subscribe To
Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 3 years in patients with geographic atrophy (ga)
SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study Well-demonstrated...
November 4, 2023, 5:37 pm
Candel therapeutics presents preclinical data from its enlighten™ discovery platform at sitc
The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate...
November 4, 2023, 12:00 pm
1 under-the-radar stock that could triple by 2030
Viking Therapeutics is looking to profit from the expanding market for obesity drugs. The company's two leading candidates are currently in phase 2 ...
November 4, 2023, 7:30 am
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Aligos therapeutics to host kol event to discuss alg-000184 phase 1, aasld late breaker data
November 16 Event to feature KOL perspective on Emerging HBV Therapies SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) — Aligos Therapeu...
November 3, 2023, 8:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting
– clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potential...
November 3, 2023, 8:05 pm
Wave life sciences third quarter 2023 financial results scheduled for november 9, 2023
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-...
November 3, 2023, 8:05 pm
Prime medicine reports third quarter 2023 financial results and provides business updates
— Presented new preclinical research across multiple programs, including proof-of-concept data from i...
November 3, 2023, 8:01 pm
Kineta reports third quarter 2023 financial results and provides corporate update
Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial...
November 3, 2023, 8:01 pm
New preliminary clinical data on potential of opus aav-based gene therapy for rare inherited retinal disease to be presented at the american academy of ophthalmology annual conference 2023
Data to be presented as part of gene augmentation therapy presentation RALEIGH, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) — Opus Genetics, a patient-focu...
November 3, 2023, 7:43 pm
Update: korro bio and frequency therapeutics announce closing of merger and private placement of $117 million
Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fu...
November 3, 2023, 7:31 pm
Cellectis: end of 2023 data readouts to boost car-t prospects
Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin...
November 3, 2023, 6:57 pm
Korro bio and frequency therapeutics announce closing of merger and private placement of $117 million
Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fu...
November 3, 2023, 4:19 pm
Quoin pharmaceuticals announces third quarter 2023 financial results and corporate update conference call to be held on thursday november 9th at 8:30 am et
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a ...
November 3, 2023, 12:41 pm
Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing ...
November 3, 2023, 12:30 pm